Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vectura Reaps Value From Pan-JAK Inhibitor For Severe Asthma

Kinaset Therapeutics To Evaluate Candidate

Executive Summary

The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.

You may also be interested in...



Private Equity Eyes Pharma As Vectura Gets Snapped Up By Carlyle

Cash-rich private equity firms are eyeing opportunities in healthcare, especially among listed companies with sluggish share prices. The Carlyle Group could be getting a bargain if it seals a deal for the Chippenham-based inhalation specialist.

Novartis CEO Touts R&D 'Wild Cards' As Proof Of Deep Pipeline

Potentially transformative treatments for severe asthma, COPD and osteoarthritis are among some of the below-the-radar projects the Swiss major is advancing, according to Vas Narasimhan. 

NAVIGATOR: Tezepelumab Could Transform Severe Uncontrolled Asthma Care

In top-line results from the Phase III NAVIGATOR study, AstraZeneca/Amgen’s human monoclonal antibody tezepelumab has significantly reduced disease exacerbations in patients with severe asthma regardless of their type of inflammation, including those with low eosinophil counts.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143404

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel